UTHR - United Therapeutics Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 53.28B
Enterprise Value 32.73B
Trailing P/E N/A
Forward P/E 19.17
PEG Ratio (5 yr expected) 11.58
Price/Sales (ttm)2.05
Price/Book (mrq)1.41
Enterprise Value/Revenue 31.71
Enterprise Value/EBITDA 6-23.42

Trading Information

Stock Price History

Beta (3Y Monthly) 0.88
52-Week Change 3-39.63%
S&P500 52-Week Change 35.54%
52 Week High 3130.00
52 Week Low 374.64
50-Day Moving Average 379.20
200-Day Moving Average 3102.11

Share Statistics

Avg Vol (3 month) 3773.34k
Avg Vol (10 day) 3468.92k
Shares Outstanding 543.81M
Float 40.79M
% Held by Insiders 11.76%
% Held by Institutions 1101.74%
Shares Short (Jun 28, 2019) 42.84M
Short Ratio (Jun 28, 2019) 42.98
Short % of Float (Jun 28, 2019) 47.45%
Short % of Shares Outstanding (Jun 28, 2019) 46.48%
Shares Short (prior month May 31, 2019) 42.83M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 21/2
Last Split Date 3Sep 23, 2009

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin -9.36%
Operating Margin (ttm)-9.67%

Management Effectiveness

Return on Assets (ttm)-2.87%
Return on Equity (ttm)-6.39%

Income Statement

Revenue (ttm)1.6B
Revenue Per Share (ttm)36.72
Quarterly Revenue Growth (yoy)-6.80%
Gross Profit (ttm)1.43B
EBITDA -116.6M
Net Income Avi to Common (ttm)-149.9M
Diluted EPS (ttm)-3.44
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.61B
Total Cash Per Share (mrq)36.64
Total Debt (mrq)1.06B
Total Debt/Equity (mrq)45.58
Current Ratio (mrq)7.19
Book Value Per Share (mrq)52.94

Cash Flow Statement

Operating Cash Flow (ttm)-124.7M
Levered Free Cash Flow (ttm)-152.41M